TeohSTYYapDYHChanTM. Ten tips in lupus nephritis management. Clin Kidney J2025; 18(1): sfae376.
2.
RovinBHFurieRLatinisK, et al.Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum2012; 64(4): 1215.
3.
MarinovADWangHBastackySI, et al.The type II anti-CD20 antibody obinutuzumab (GA101) is more effective than rituximab at depleting B cells and treating disease in a murine lupus model. Arthritis Rheumatol2021; 73(5): 826.
4.
ReddyVKleinCIsenbergDA, et al.Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology2017; 56(7): 1227.
5.
TurCEcksteinMVeldenJ, et al.CD19-CAR T-cell therapy induces deep tissue depletion of B cells. Ann Rheum Dis2024; 84: 106–114.
6.
HerterSHertingFMundiglO, et al.Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Therapeut2013; 12(10): 2031.
7.
FurieRAArocaGCascinoMD, et al.B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis2022; 81(1): 100.
8.
FurieRARovinBHGargJP, et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med2025. doi:10.1056/NEJMoa2410965.
9.
KvacskayPMerktWGüntherJ, et al.Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series. Ann Rheum Dis2022; 81(5): 744.
